Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Asterias Biotherapeutics

- PMLiVE

Merck’s Keytruda granted FDA approval for expanded use in lung cancer

The approval marks the sixth non-small cell lung cancer indication for the anti-PD-1 therapy

- PMLiVE

Pfizer announces FDA approval for Braftovi/Mektovi combination in lung cancer

Non-small cell lung cancer accounts for approximately 85% of all lung cancers cases

- PMLiVE

BMS presents positive six-year results for Opdivo/Yervoy combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

- PMLiVE

NIHR awards £2.3m for AI study to improve radiotherapy for lung cancer

The AI tool is expected to help doctors plan each patient’s radiotherapy treatment

- PMLiVE

Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

The drug is now the first ALK inhibitor to show disease-free survival benefit in this patient population

- PMLiVE

Roche’s Genentech and Blueprint receive full FDA approval for Gavreto in lung cancer

The targeted therapy was granted accelerated approval for the NSCLC indication in 2020

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 lung cancer study

The investigational drug met the dual primary endpoint of progression-free survival

- PMLiVE

Amgen’s Lumakras shows promise in phase 3 lung cancer study

The company has also presented results from a study of Lumakras in colorectal cancer

- PMLiVE

AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

BMS presents positive four-year results for Opdivo combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

- PMLiVE

AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

AI model shows promise in detecting lung cancer earlier

Lung cancer accounts for more than 20% of cancer deaths in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links